Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRANITE-001: Personalized Neoantigen Vaccine + Nivolumab/Ipilimumab in Advanced Solid Tumors
NCT03639714Phase 2Completed
- Sponsor
- Gritstone bio, Inc.
- Start
- Feb 2019
- Primary completion
- Nov 2022
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of GRT-C901, GRT-R902 in colorectal cancer (CRC), gastroesophageal adenocarcinoma, urothelial carcinoma (UC), sponsored by Gritstone bio, Inc.. Started Feb 2019; status: completed.
02
Drugs
GRT-C901GRT-R902
03
Conditions
colorectal cancer (CRC)gastroesophageal adenocarcinomaurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03639714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639714.